Related Experiment Video
Updated: Dec 12, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human
Michael W Leach1, David O Clarke2, Sherri Dudal3
1Drug Safety Research and Development, Pfizer, Inc., Cambridge, Massachusetts, USA.
The minimum anticipated biological effect level (MABEL) approach for new molecular entities (NMEs) may hinder drug development. A new framework offers a data-driven, risk-based method for selecting first-in-human starting doses.
Area of Science:
- Pharmaceutical Sciences
- Clinical Pharmacology
- Drug Development
Background:
- First-in-human (FIH) starting dose selection for new molecular entities (NMEs) aims to minimize subject risk.
- The minimum anticipated biological effect level (MABEL) approach is conservative, prioritizing safety for high-risk NMEs.
- Concerns exist regarding MABEL's overuse for lower-risk molecules, potentially delaying drug development and patient access.
More Related Videos
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
Drug Discovery: Overview
Dosage Regimens: Partial Pharmacokinetic Parameters
Preclinical Development: Overview
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Dosage Regimens: Designs and Approaches